Cargando...
Cabozantinib for the treatment of kidney cancer
INTRODUCTION: Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. AREAS COVERE...
Guardado en:
| Publicado en: | Expert Rev Anticancer Ther |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6166873/ https://ncbi.nlm.nih.gov/pubmed/28633552 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14737140.2017.1344553 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|